Abstract
Alzheimers disease (AD) is characterized by two major features: (1) degeneration of basal forebrain cholinergic neurons and ensuing deficient cholinergic functions in cortex and hippocampus; (2) extracellular protein aggregates containing β-amyloid peptides (Aβ) in these cholinergic target areas. So far, the most effective therapy for AD is to enhance cholinergic transmission. Neuromodulatory functions of the cholinergic system are mainly mediated by muscarinic receptors (mAChRs). It has long been recognized that mAChRs are crucial for the control of high-level cognitive processes. Drugs that activate mAChRs are helpful in ameliorating cognitive deficits of AD. On the other hand, mounting evidence have established detrimental effects of Aβ to cognitive functions. Despite intensive research on AD, it remains unclear how these two prominent features of the disease may be linked to cause cognitive impairments. In this review, we will summarize a series of recent findings on the interactions between cholinergic functions and β-amyloid in normal animals and AD models, and discuss their potential implications in the pathophysiology and treatment of Alzheimers disease.
Keywords: alzheimers disease, cholinergic, muscarinic receptors, amyloid peptides, insulin, gabaergic transmission, prefrontal cortex, protein kinase c
Current Alzheimer Research
Title: Alzheimers Disease: Interactions Between Cholinergic Functions and β- amyloid
Volume: 1 Issue: 4
Author(s): Zhen Yan and Jian Feng
Affiliation:
Keywords: alzheimers disease, cholinergic, muscarinic receptors, amyloid peptides, insulin, gabaergic transmission, prefrontal cortex, protein kinase c
Abstract: Alzheimers disease (AD) is characterized by two major features: (1) degeneration of basal forebrain cholinergic neurons and ensuing deficient cholinergic functions in cortex and hippocampus; (2) extracellular protein aggregates containing β-amyloid peptides (Aβ) in these cholinergic target areas. So far, the most effective therapy for AD is to enhance cholinergic transmission. Neuromodulatory functions of the cholinergic system are mainly mediated by muscarinic receptors (mAChRs). It has long been recognized that mAChRs are crucial for the control of high-level cognitive processes. Drugs that activate mAChRs are helpful in ameliorating cognitive deficits of AD. On the other hand, mounting evidence have established detrimental effects of Aβ to cognitive functions. Despite intensive research on AD, it remains unclear how these two prominent features of the disease may be linked to cause cognitive impairments. In this review, we will summarize a series of recent findings on the interactions between cholinergic functions and β-amyloid in normal animals and AD models, and discuss their potential implications in the pathophysiology and treatment of Alzheimers disease.
Export Options
About this article
Cite this article as:
Yan Zhen and Feng Jian, Alzheimers Disease: Interactions Between Cholinergic Functions and β- amyloid, Current Alzheimer Research 2004; 1 (4) . https://dx.doi.org/10.2174/1567205043331992
DOI https://dx.doi.org/10.2174/1567205043331992 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer’s disease
Current Alzheimer Research Synthesis and Bioevaluation of Quaternary Centered 3-hydroxy-3 (alkynyl)indolin-2-one Derivatives as Potential Cytotoxic Agents and Akt Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Characterization of Cancer Stem Cells and Primary Cilia in Medulloblastoma
CNS & Neurological Disorders - Drug Targets Disodium Phosphate of Novel Pyrazole-Linked Norcantharidin Analogs:Design, Synthesis and their Anticancer Evaluation
Letters in Drug Design & Discovery GSK-3 Inhibitors as New Leads to Treat Type-II Diabetes
Current Drug Targets Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology A Review of Recent Developments in Nanocellulose-Based Conductive Hydrogels
Current Nanoscience Cell Metabolism Under Microenvironmental Low Oxygen Tension Levels in Stemness, Proliferation and Pluripotency
Current Molecular Medicine Protein Arginine Methyltransferase 1 and its Dynamic Regulation Associated with Cellular Processes and Diseases
Protein & Peptide Letters N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
Current Alzheimer Research Anticancer Agents: VTA or VDA
Current Bioactive Compounds Therapeutic Targets in Extracellular Protein Deposition Diseases
Current Medicinal Chemistry Pharmacological Actions and Underlying Mechanisms of Catechin: A Review
Mini-Reviews in Medicinal Chemistry Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Endocytosis, Intracellular Traffic and Fate of Cell Penetrating Peptide Based Conjugates and Nanoparticles
Current Pharmaceutical Design Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets Neuroprotection with Natural Antioxidants and Nutraceuticals in the Context of Brain Cell Degeneration: The Epigenetic Connection
Current Topics in Medicinal Chemistry